Molecular genetics of Mycobacterium tuberculosis resistant to aminoglycosides and cyclic peptide testing by MTBDRsl in Armenia | Zendy

Hasmik Margaryan | Zendy; Parissa Farnia | Zendy; Արմեն Հայրապետյան | Zendy; A.A. Mirzoyan | Zendy

Open Access

Molecular genetics of Mycobacterium tuberculosis resistant to aminoglycosides and cyclic peptide testing by MTBDRsl in Armenia

Author(s) -

Hasmik Margaryan,

Parissa Farnia,

Արմեն Հայրապետյան,

A.A. Mirzoyan

Publication year - 2016

Publication title -

international journal of mycobacteriology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.53

H-Index - 20

eISSN - 2212-554X

pISSN - 2212-5531

DOI - 10.1016/j.ijmyco.2016.07.010

Subject(s) - mycobacterium tuberculosis , genetics , virology , biology , microbiology and biotechnology , tuberculosis , medicine , pathology

The GenoType MTBDRsl test rapidly detects resistance to ethambutol, fluoroquinolones, second-line aminoglycosides (amikacin [AMK] and kanamycin [KAN]), and cyclic peptides (capreomycin [CAP]) in Mycobacterium tuberculosis. According to data from Global Drug Resistance Surveillance Report (2007), Armenia is counted as a high-burden country for multidrug-resistant tuberculosis (MDR-TB). The estimated burden of MDR-TB in 2012 was 9.4 (7-12) and 43 (38-49) among retreatment TB cases. A total of 92 laboratory confirmed cases were reported to the World Health Organization (57 new and 35 previously treated) out of 511 cases tested for MDR-TB.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research